Slides
Page 1
E A R N I N G S P R E S E N T A T I O N O C T O B E R 2 0 2 6 www.acutaas.com www.acutaas.com
Page 2
Earnings Presentation | October 2026 Management Commentary 2 Mr. Naresh Patel Executive Chairman and Managing Director YoY ▲ 42.7% Revenue for Q2 FY27 ₹4,369 (Mn.) YoY ▲ 84.6% EBITDA for Q2 FY27 ₹1,760 YoY ▲ 71.4% PAT for Q2 FY27 ₹1,231 “We delivered strong revenue of ₹4,369 million, representing 42.7% year-on-year growth. The performance was led by the continued momentum in our Pharmaceutical Intermediates business, which was offset by softer performance in the Specialty Chemicals segment. A significant milestone during the quarter was the inauguration of our South Korea manufacturing facility ahead of schedule. The facility is equipped to produce high-purity chemicals used in photoresists, semiconductor packaging materials, etching materials and other semiconductor applications, positioning us to capitalize on opportunities in the fast-growing semiconductor ecosystem. Improved revenue visibility and robust order pipeline gives me confidence to revise our FY27 revenue growth guidance upward from 25% to around 30%. We are also raising our EBITDA margin guidance to 38-40% range.”
Page 3
Earnings Presentation | October 2026 Q2 FY27 Financial Performance – Key Metrics 3 Revenue from Operations Q2 FY27 Earnings & Business Highlights 2,626 436 3,062 4,020 349 4,369 Advance Intermediates Specialty Chemicals Total Q2FY26 Q2FY27 EBITDA & EBITDA Margin PAT (₹ Mn.) (₹ Mn.)(₹ Mn) 953 1,760 31.1% 40.3% Q2FY26 Q2FY27 EBITDA EBITDA Margin 719 1,231 23.5% 28.2% Q2FY26 Q2FY27 PAT PAT Margin 53.1% (20.0%) 42.7% YoY Growth Pharma Intermediates CDMO as well as Core Advanced intermediate business delivered robust growth Specialty Chemicals Decline in Commodity chemicals revenue part of the strategy to gradually phase out the products; BFC business was impacted during the quarter Due to change in ownership of the US customer EBITDA Margins Superior margins for the quarter were driven by higher gross margins as well as operating leverage PAT Margin The strength in PAT margins was primarily driven by solid EBITDA margins, offset to an extent by higher depreciation expenses, and lower other income
Page 4
Earnings Presentation | October 2026 H1 FY27 Financial Performance – Key Metrics 4 Revenue from Operations 4,284 850 5,134 6,947 718 7,665 Advance Intermediates Specialty Chemicals Total H1FY26 H1FY27 EBITDA & EBITDA Margin PAT (₹ Mn.) (₹ Mn.)(₹ Mn) 1,462 2,890 28.5% 37.7% H1FY26 H1FY27 EBITDA EBITDA Margin 1,159 1,981 22.6% 25.8% H1FY26 H1FY27 PAT PAT Margin 62.2% (15.6%) 49.3% YoY Growth
Page 5
Earnings Presentation | October 2026 Q2 & H1 FY27 Financial Performance – P&L Statement 5 Particulars (Rs. Mn) Q2FY27 Q2FY26 YoY Q1FY27 QoQ H1FY27 H1FY26 YoY Revenue from Operations 4,369 3,062 42.7% 3,297 32.5% 7,666 5,134 49.3% COGS 1,654 1,355 1,388 3,042 2,323 Gross Profit 2,715 1,707 59.0% 1,909 42.2% 4,624 2,811 64.5% Gross Margin 62.1% 55.8% 57.9% 60.3% 54.7% Employee benefits expenses 421 294 396 816 544 Other expenses 535 461 383 917 804 Total Expenses 2,610 2,109 2,166 4,776 3,672 EBITDA 1,760 953 84.6% 1,131 55.6% 2,890 1,462 97.7% EBITDA Margin 40.3% 31.1% 34.3% 37.7% 28.5% Depreciation and amortization 127 84 98 225 165 PBIT 1,633 869 87.8% 1,032 58.1% 2,665 1,297 105.5% Finance costs 10 6 11 22 12 Other Income 51 98 18 69 258 PBT 1,674 962 74.0% 1,039 61.1% 2,713 1,543 75.9% Tax Expense 442 243 289 731 384 PAT 1,231 719 71.4% 750 64.2% 1,981 1,159 71.0% PAT Margin 28.2% 23.5% 22.7% 25.8% 22.6%
Page 6
Earnings Presentation | October 2026 Financial Performance over the years – Key Metrics 6 Revenue from Operations- Growth Trends 3,240 166 3,406 4,270 932 5,201 5,180 990 6,170 5,678 1,497 7,175 8,540 1,529 10,069 11,741 1,652 13,394 6,947 718 7,665 Advance Intermediates Chemicals Total FY21 FY22 FY23 FY24 FY25 FY26 H1 FY27 (₹ Mn.) 29.4% 58.3% 31.5% FY21-26 CAGR: # ROE and ROCE adjusted for Cash & Cash Equivalents, Exceptional Items, CWIP 540 719 833 808 1,604 3,564 1,981 15.9% 13.8% 13.5% 11.3% 15.9% 26.6% 25.8% FY21 FY22 FY23 FY24 FY25 FY26 H1 FY27 PAT (₹ Mn) PAT Margin (%) PAT and PAT Margins (₹ Mn & %) 30.7% 19.2% 19.7% 12.6% 19.1% 39.3% 34.4% 32.4% 13.8% 18.7% 11.4% 15.1% 32.5% 25.7% 0.0% 5.0% 10.0% 15.0% 20.0% 25.0% 30.0% 35.0% 40.0% 45.0% 50.0% FY21 FY22 FY23 FY24 FY25 FY26 H1 FY27 ROCE ROE Returns Profile# 95% 83% 84% 79% 85% 88% 91% 5% 18% 16% 21% 15% 12% 9% FY21 FY22 FY23 FY24 FY25 FY26 H1 FY27 Pharma Intermediates Specialty Chemicals Revenue – by Business Verticals (%) 802 1,052 1,227 1,285 2,321 4,804 2,890 23.5% 20.2% 19.9% 17.9% 23.0% 35.9% 37.7% FY21 FY22 FY23 FY24 FY25 FY26 H1 FY27 EBITDA (₹ Mn) EBITDA Margin (%) EBITDA and EBITDA Margins (₹ Mn. & %) Note: PAT for FY24 is adjusted for Exceptional Items (%)
Page 7
Earnings Presentation | October 2026 Financial Performance over the years - Profit and Loss 7 Particulars (₹ Mn.) FY21 FY22 FY23 FY24 FY25 FY26 H1 FY27 Revenue from Operations 3,406 5,201 6,167 7,175 10,069 13,394 7,666 Other Income 14 28 43 75 169 416 69 Total Income 3,420 5,229 6,210 7,250 10,238 13,810 7,735 Cost of materials consumed 1,749 2,823 3,459 4,402 5,698 5,950 3,223 Changes in Inventories¹ 48 (95) (150) (285) (176) (290) (181) Employee benefits expenses 210 414 488 631 837 1,176 816 Finance cost 56 64 24 59 62 33 22 Depreciation and amortisation expenses 42 101 123 161 266 360 225 Other expenses 598 1,008 1,144 1,142 1,390 1,754 599 Total Expense 2,703 4,315 5,088 6,110 8,077 8,982 4,704 Profit before tax and exceptional items 717 914 1,122 1,140 2,162 4,827 2,713 Exceptional profit / (loss) - - - (321) - - - Tax expense 177 195 289 332 557 1,264 731 Profit for the year 540 719 833 487 1,604 3,564 1,981 ¹ Changes in inventories of finished goods, traded goods and work -in-progress
Page 8
Earnings Presentation | October 2026 Financial Performance over the years - Balance Sheet 8 Assets (₹ Mn.) FY21 FY22 FY23 FY24 FY25 FY26 H1 FY27 Property, plant and equipment 1,422 1,584 1,844 3,229 4,629 5,828 9,545 Right of use assets 184 194 374 372 424 505 500 Capital work-in-progress 2 30 255 1,254 1,303 3,324 669 Goodwill - - 203 568 568 1,043 1,043 Other intangible assets 257 267 211 103 83 72 61 Investments 14 17 17 2 2 2 2 Other financial assets 27 108 65 26 49 82 81 Current tax assets (net) - 49 32 25 2 - 48 Other non-current assets 64 97 129 447 517 171 139 Total non-current assets 1,970 2,346 3,130 6,026 7,577 11,027 12,089 Inventories 604 1,122 1,192 1,567 1,799 2,313 2,803 Trade receivables 1,207 1,637 2,303 2,064 2,905 3,626 3,583 Cash and cash equivalents 27 103 305 297 1,852 2,156 2,888 Other bank balances - 893 281 236 637 93 181 Loans 3 6 13 16 22 26 26 Other current assets 321 481 445 753 701 599 640 Total current assets 2,162 4,291 4,571 4,958 7,916 8,813 10,120 Total assets 4,133 6,589 7,669 10,959 15,493 19,840 22,209 Liabilities & Equity (₹ Mn.) FY21 FY22 FY23 FY24 FY25 FY26 H1 FY27 Shareholder's equity 1,669 5,223 5,939 6,828 13,201 17,108 19,204 Financial Liabilities 726 6 6 1,136 48 91 93 Provisions 44 4 7 13 25 46 25 Deferred tax liabilities (net) 33 63 88 130 196 287 354 Total non-current liabilities 803 73 101 1,280 269 424 471 Borrowings 640 3 30 1,030 82 265 59 Trade payables 848 1,184 1420 1,346 1,561 1,539 1,558 Other current liabilities 151 46 64 344 135 124 448 Provisions 10 60 114 132 245 325 470 Current tax liabilities (net) 11 - - - - 55 - Total current liabilities 1,660 1,293 1,628 2,852 2,023 2,308 2,534 Total liabilities 2,463 1,366 1,730 4,131 2,292 2,732 3,005 Total equity and liabilities 4,133 6,589 7,669 10,959 15,493 19,840 22,209
Page 9
Earnings Presentation | October 2026 Promoters 32.7% MF 14.4% Other DII 5.0% FII 22.6% Others 25.3% Shareholder Information 9 Source: NSE Shareholding as on 30th September 2026 Share Information as on 30th September 2026 Source: NSE NSE Ticker ACUTAAS BSE Ticker 543349 Market Cap (₹ Cr.) 29,208 Shares Outstanding 8,18,71,122 3M ADTV (Shares) 3,47,404 3M ADTV (₹ Cr.) 115.7 Industry Specialty Chemicals
Page 10
Earnings Presentation | October 2026 Safe Harbor 10 The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor should subscribe / purchase the company shares. The Company makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information contained herein. This presentation may include certain “forward looking statements”. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others, general economic and business conditions in India and abroad, ability to successfully implement our strategy, our research & development efforts, our growth & expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global pharmaceutical and chemical industries, increasing competition, changes in political conditions in India or any other country and changes in the foreign exchange control regulations in India. Neither the company, nor its Directors and any of the affiliates or employee have any obligation to update or otherwise revise any forward-looking statements. The readers may use their own judgment and are advised to make their own calculations before deciding on any matter based on the information given herein. No part of this presentation may be reproduced, quoted or circulated without prior written approval from Acutaas Chemicals Ltd.
Page 11
Contact Us For more information please contact: www.acutaas.com www.acutaas.com Acutaas Chemicals Limited Ekta Srivastava Company Secretary & Compliance Officer cs@acutaas.com Rahul Thakur Senior Manager – Investor Relations Rahul.thakur@acutaas.com Disclaimer: This presentation contains forward-looking statements. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results.